Cancer patients get extra shield against COVID-19 in groundbreaking trial
NCT ID NCT04442048
Summary
This study tested whether an immune-stimulating shot called IMM-101 could help prevent severe respiratory and COVID-19 infections in cancer patients. It involved 195 adults with cancer who were at higher risk for severe infections due to their age, health conditions, or cancer treatments. Participants were randomly assigned to receive the IMM-101 shot or to be observed without it, to see if the shot reduced serious illness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4, Canada
-
CIUSSS de l'Estrie - Centre hospitalier
Sherbrooke, Quebec, J1H 5N4, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
London Regional Cancer Program
London, Ontario, N6A 5W9, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
The Research Institute of the McGill University
Montreal, Quebec, H4A 3J1, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.